title: Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
abstract: OBJECTIVE
  Compare observed and forecasted efficacy of mixed amphetamine salts extended release (MAS-XR; Adderall) with atomoxetine (Strattera) in ADHD children.
  
  
  METHODS
  The authors analyze data from a randomized, double-blind, multicenter, parallel-group, forced-dose-escalation laboratory school study of children ages 6 to 12 with ADHD combined or hyperactive/impulsive type. Primary efficacy measures are attention and deportment scores on the SKAMP behavioral rating scale, and secondary efficacy measures are academic performance scores from the PERMP test.
  
  
  RESULTS
  MAS-XR elicits greater improvements than atomoxetine in each domain within 3 weeks of treatment, including attention, number of math problems attempted and correct, and overall clinical functioning. Treatment differences in each outcome measure at subsequent weeks are projected from generalized estimating equations to become greater with the duration of extension of the treatment regimen.
  
  
  CONCLUSIONS
  This study suggests that relative advantages of MAS-XR seen in the first 3 weeks are likely to be maintained in subsequent weeks.
authors.affiliation: State University of New York Upstate Medical University, NY, USA.
authors.forename: Stephen V
authors.initials: SV
authors.lastname: Faraone
authors.forename: Sharon B
authors.initials: SB
authors.lastname: Wigal
authors.forename: Paul
authors.initials: P
authors.lastname: Hodgkins
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000662:Amphetamines / Q000009:adverse effects / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001288:Attention / Q000187:drug effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy*; D019958:Attention Deficit and Disruptive Behavior Disorders / Q000175:diagnosis / Q000188:drug therapy; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D008297:Male; D011340:Problem Solving / Q000187:drug effects; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000662:Amphetamines; D000697:Central Nervous System Stimulants; D011437:Propylamines; C449521:SLI381; D000069445:Atomoxetine Hydrochloride